Cyclic peptide FXII inhibitor provides safe anticoagulation in a thrombosis model and in artificial lungs.
Animals
Anticoagulants
/ pharmacology
Blood Coagulation
/ drug effects
Chlorides
/ adverse effects
Cloning, Molecular
Disease Models, Animal
Drug Discovery
Extracorporeal Membrane Oxygenation
/ methods
Factor XII
/ antagonists & inhibitors
Factor XIIa
/ antagonists & inhibitors
Female
Ferric Compounds
/ adverse effects
Humans
Lung
Male
Mice
Mice, Inbred C57BL
Mice, Knockout
Peptides, Cyclic
/ drug effects
Rabbits
Recombinant Proteins
/ pharmacology
Swine
Thrombosis
/ prevention & control
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
04 08 2020
04 08 2020
Historique:
received:
13
11
2019
accepted:
08
07
2020
entrez:
6
8
2020
pubmed:
6
8
2020
medline:
12
9
2020
Statut:
epublish
Résumé
Inhibiting thrombosis without generating bleeding risks is a major challenge in medicine. A promising solution may be the inhibition of coagulation factor XII (FXII), because its knock-out or inhibition in animals reduced thrombosis without causing abnormal bleeding. Herein, we have engineered a macrocyclic peptide inhibitor of activated FXII (FXIIa) with sub-nanomolar activity (K
Identifiants
pubmed: 32753636
doi: 10.1038/s41467-020-17648-w
pii: 10.1038/s41467-020-17648-w
pmc: PMC7403315
doi:
Substances chimiques
Anticoagulants
0
Chlorides
0
Ferric Compounds
0
Peptides, Cyclic
0
Recombinant Proteins
0
Factor XII
9001-30-3
Factor XIIa
EC 3.4.21.38
ferric chloride
U38V3ZVV3V
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3890Références
Raskob, G. E. et al. Thrombosis: a major contributor to global disease burden: ISTH steering committee for world thrombosis day the members of the ISTH steering committee for world thrombosis day. Thromb. Res. 134, 931–938 (2014).
Eikelboom, J. W. & Weitz, J. I. Update on antithrombotic therapy: new anticoagulants. Circulation 121, 1523–1532 (2010).
pubmed: 20368532
Schulman, S. & Crowther, M. A. How I anticoagulate in 2012, new and old anticoagulant agents, and when and how to switch. Blood 119, 3016–3023 (2012).
pubmed: 22302737
Liew, A., Eikelboom, J. W., O’Donnell, M. & Hart, R. G. Assessment of anticoagulation intensity and management of bleeding with old and new oral anticoagulants. Can. J. Cardiol. 29, S34–S44 (2013).
pubmed: 23790596
Kenne, E. et al. Factor XII: a novel target for safe prevention of thrombosis and inflammation. J. Intern. Med. 278, 571–585 (2015).
pubmed: 26373901
Gailani, D., Bane, C. E. & Gruber, A. Factor XI and contact activation as targets for antithrombotic therapy. J. Thromb. Haemost. 13, 1383–1395 (2015).
pubmed: 25976012
pmcid: 4516614
Weidmann, H. et al. The plasma contact system, a protease cascade at the nexus of inflammation, coagulation and immunity. Biochim. Biophys. Acta. Mol. Cell Res. 1864, 2118–2127 (2017).
pubmed: 28743596
Renné, T. et al. Defective thrombus formation in mice lacking coagulation factor XII. J. Exp. Med. 202, 271–281 (2005).
pubmed: 16009717
pmcid: 2213000
Kokoye, Y. et al. A comparison of the effects of factor XII deficiency and prekallikrein deficiency on thrombus formation. Thromb. Res. 140, 118–124 (2016).
pubmed: 26950760
pmcid: 4821716
Kleinschnitz, C. et al. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J. Exp. Med. 203, 513–518 (2006).
pubmed: 16533887
pmcid: 2118228
Pauer, H.-U. et al. Targeted deletion of murine coagulation factor XII gene-a model for contact phase activation in vivo. Thromb. Haemost. 92, 503–508 (2004).
pubmed: 15351846
Revenko, A. S. et al. Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding. Blood 118, 5302–5311 (2011).
pubmed: 21821705
pmcid: 4425441
Yau, J. W. et al. Selective depletion of factor XI or factor XII with antisense oligonucleotides attenuates catheter thrombosis in rabbits. Blood 123, 2102–2107 (2014).
pubmed: 24501216
Larsson, M. et al. A factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk. Sci. Transl. Med. 6, 222ra17–222ra17 (2014).
pubmed: 24500405
Matafonov, A. et al. Factor XII inhibition reduces thrombus formation in a primate thrombosis model. Blood 123, 1739–1746 (2014).
pubmed: 24408325
pmcid: 3954054
Yau, J. W. et al. Corn trypsin inhibitor coating attenuates the prothrombotic properties of catheters in vitro and in vivo. Acta Biomater. 8, 4092–4100 (2012).
pubmed: 22824529
Xu, Y. et al. Factor XIIa inhibition by Infestin-4: in vitro mode of action and in vivo antithrombotic benefit. Thromb. Haemost. 111, 694–704 (2013).
pubmed: 24336918
Barbieri, C. M. et al. Factor XIIa as a novel target for thrombosis: target engagement requirement and efficacy in a rabbit model of microembolic signals. J. Pharmacol. Exp. Ther. 360, 466–475 (2017).
pubmed: 28035006
Long, A. T., Kenne, E., Jung, R., Fuchs, T. A. & Renné, T. Contact system revisited: an interface between inflammation, coagulation, and innate immunity. J. Thromb. Haemost. 14, 427–437 (2016).
pubmed: 26707513
Sniecinski, R. M. & Chandler, W. L. Activation of the hemostatic system during cardiopulmonary bypass. Anesth. Analg. 113, 1319–1333 (2011).
pubmed: 22003219
Esper, S. A., Levy, J. H., Waters, J. H. & Welsby, I. J. Extracorporeal membrane oxygenation in the adult: a review of anticoagulation monitoring and transfusion. Anesth. Analg. 118, 731–743 (2014).
pubmed: 24651227
Annich, G. M., Zaulan, O., Neufeld, M., Wagner, D. & Reynolds, M. M. Thromboprophylaxis in extracorporeal circuits: current pharmacological strategies and future directions. Am. J. Cardiovasc. Drugs 17, 425–439 (2017).
pubmed: 28536932
Nickel, K. F., Long, A. T., Fuchs, T. A., Butler, L. M. & Renné, T. Factor XII as a therapeutic target in thromboembolic and inflammatory diseases. Arterioscler. Thromb. Vasc. Biol. 37, 13–20 (2017).
pubmed: 27834692
Björkqvist, J., Sala-Cunill, A. & Renné, T. Hereditary angioedema: a bradykinin-mediated swelling disorder. Thromb. Haemost. 109, 368–374 (2013).
pubmed: 23306453
Krupka, J. et al. The coagulation factor XIIa inhibitor rHA-Infestin-4 improves outcome after cerebral ischemia/reperfusion injury in rats. PLoS ONE 11, e0146783 (2016).
pubmed: 26815580
pmcid: 4731395
Zamolodchikov, D., Chen, Z.-L., Conti, B. A., Renné, T. & Strickland, S. Activation of the factor XII-driven contact system in Alzheimer’s disease patient and mouse model plasma. Proc. Natl Acad. Sci. USA 112, 201423764 (2015).
Chen, Z.-L. et al. Depletion of coagulation factor XII ameliorates brain pathology and cognitive impairment in Alzheimer’s disease mice. Blood 129, 2547–2556 (2017).
Göbel, K. et al. Blood coagulation factor XII drives adaptive immunity during neuroinflammation via CD87-mediated modulation of dendritic cells. Nat. Commun. 7, 11626 (2016).
pubmed: 27188843
pmcid: 4873982
Björkqvist, J. et al. Defective glycosylation of coagulation factor XII underlies hereditary angioedema type III. J. Clin. Invest. 125, 3132–3146 (2015).
pubmed: 26193639
pmcid: 4563738
Australian New Zealand Clinical Trials Registry. https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=371625 (2016)
Kenne, E. & Renné, T. Factor XII: a drug target for safe interference with thrombosis and inflammation. Drug Discov. Today 19, 1459–1464 (2014).
pubmed: 24993156
Bouckaert, C. et al. Synthesis, evaluation and structure-activity relationship of new 3-carboxamide coumarins as FXIIa inhibitors. Eur. J. Med. Chem. 110, 181–194 (2016).
Baeriswyl, V. et al. A synthetic factor XIIa inhibitor blocks selectively intrinsic coagulation initiation. ACS Chem. Biol. 10, 1861–1870 (2015).
pubmed: 25989088
Middendorp, S. J. et al. Peptide macrocycle inhibitor of coagulation factor XII with subnanomolar affinity and high target selectivity. J. Med. Chem. 60, 1151–1158 (2017).
pubmed: 28045547
Wilbs, J., Middendorp, S. J. & Heinis, C. Improving the binding affinity of in-vitro-evolved cyclic peptides by inserting atoms into the macrocycle backbone. ChemBioChem 17, 2299–2303 (2016).
pubmed: 27862752
Duehrkop, C. & Rieben, R. Ischemia/reperfusion injury: effect of simultaneous inhibition of plasma cascade systems versus specific complement inhibition. Biochem. Pharmacol. 88, 12–22 (2014).
pubmed: 24384116
Barr, J. D., Chauhan, A. K., Schaeffer, G. V., Hansen, J. K. & Motto, D. G. Red blood cells mediate the onset of thrombosis in the ferric chloride murine model. Blood 121, 3733–3741 (2013).
pubmed: 23343833
pmcid: 3643770
Ciciliano, J. C. et al. Resolving the multifaceted mechanisms of the ferric chloride thrombosis model using an interdisciplinary microfluidic approach. Blood 126, 817–824 (2015).
pubmed: 25931587
pmcid: 4528067
Gailani, D. & Renne, T. Intrinsic pathway of coagulation and arterial thrombosis. Arterioscler. Thromb. Vasc. Biol. 27, 2507–2513 (2007).
pubmed: 17916770
Ghosh, A. et al. Platelet CD36 mediates interactions with endothelial cell-derived microparticles and contributes to thrombosis in mice. J. Clin. Invest. 118, 1934–1943 (2008).
pubmed: 18431509
pmcid: 2323190
WANG, X. et al. Effects of factor IX or factor XI deficiency on ferric chloride-induced carotid artery occlusion in mice. J. Thromb. Haemost. 3, 695–702 (2005).
pubmed: 15733058
Thiagarajan, R. R. et al. Extracorporeal life support organization registry international report 2016. ASAIO J. 63, 60–67 (2017).
pubmed: 27984321
Dalton, H. J. et al. Association of bleeding and thrombosis with outcome in extracorporeal life support. Pediatr. Crit. Care Med. 16, 167–174 (2015).
pubmed: 25647124
pmcid: 4605822
Zorzi, A., Middendorp, S. J., Wilbs, J., Deyle, K. & Heinis, C. Acylated heptapeptide binds albumin with high affinity and application as tag furnishes long-acting peptides. Nat. Commun. 8, 1–9 (2017).
Banz, Y. et al. Locally targeted cytoprotection with dextran sulfate attenuates experimental porcine myocardial ischaemia/reperfusion injury. Eur. Heart J. 26, 2334–2343 (2005).
pubmed: 16055495
Angelillo-Scherrer, A. et al. Connexin 37 limits thrombus propensity by downregulating platelet reactivity. Circulation 124, 930–939 (2011).
pubmed: 21810657